Novartis India Ltd (NOVARTIND)
₹1,686.00
Mkt cap
₹4,476 Cr
P/E ratio
45.80
P/B
5.09
Div yield
0.00%
ROE
11.60%
ROCE
16.30%
EPS (TTM)
₹36.81
Book value
₹331
52W range
592–2,589
Sector
Healthcare
Price history
Previous close
Novartis India Ltd is primarily engaged in the Business of Wholesale of pharmaceuticals and medical goods. [1] It imports various medicines to India from different sources across the globe. [2]
NSE NOVARTINDBSE 500672
Health check
Cautious
ValuationExpensive
ProfitabilityAverage
GrowthLow
TechnicalsNeutral
52-week range
−34.87% from high₹1,686
₹592+184.73% from low₹2,589
Current
₹1,686.00
Prev close
₹1,815.00
Day
−7.11%
Price performance
1D
−7.11%
1W
−7.59%
1M
−12.37%
3M
+7.01%
6M
+63.21%
1Y
+182.22%
YTD
+69.37%
Financials
Revenue, profit & margin
P/E ratio
45.8×
NOVARTIND is 33% above the sector median of 34.5×
NOVARTIND45.8×
Sector median34.5×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 91 | 79 | 85 | 81 | 92 | 87 | 93 | 84 | 88 | 90 | 86 | 91 | 104 | |
| Expenses | 73 | 62 | 65 | 70 | 68 | 69 | 67 | 60 | 60 | 66 | 64 | 70 | 69 | |
| Operating Profit | 17 | 17 | 20 | 11 | 24 | 18 | 26 | 24 | 27 | 24 | 22 | 21 | 35 | |
| OPM % | 19% | 21% | 23% | 14% | 26% | 21% | 28% | 29% | 31% | 26% | 26% | 23% | 34% | |
| Other Income | 12 | 17 | 22 | 10 | 10 | 10 | 11 | 11 | 11 | 9 | 9 | 10 | 9 | |
| Interest | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | |
| Depreciation | 2 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | |
| Profit before tax | 28 | 32 | 41 | 21 | 34 | 28 | 35 | 34 | 37 | 33 | 30 | 30 | 43 | |
| Tax % | 27% | 27% | 36% | 31% | 24% | 26% | 28% | 14% | 26% | 26% | 46% | 16% | 25% | |
| Net Profit | 20 | 24 | 27 | 15 | 26 | 20 | 25 | 29 | 28 | 24 | 16 | 25 | 32 | |
| EPS in Rs | 8.21 | 9.59 | 10.76 | 5.95 | 10.42 | 8.27 | 10.31 | 11.87 | 11.19 | 9.81 | 6.52 | 10.23 | 13.05 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202670.68%Promoter
Promoters70.68%
FIIs1.21%1.05
DIIs1.50%0.15
Public26.61%1.20
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,761.00 | 33.45 | 4,22,523 | 0.91% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,664.00 | 86.11 | 2,56,549 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,580.00 | 80.24 | 1,74,208 | 0.83% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,244.00 | 90.49 | 1,21,246 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,184.40 | 24.27 | 1,18,144 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,345.00 | 40.10 | 1,12,265 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,358.00 | 35.33 | 1,09,709 | 0.96% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Novartis India | ₹1,812.80 | 45.78 | 4,476 | 0.00% | 32 | +16.62% | 104 | +18.57% | 16.26% |
| Median: 159 Co. | ₹439.10 | 34.49 | 1,934 | 0.08% | 14 | +22.88% | 170 | +18.91% | 15.11% |
Filings
Annual reports15
Concall transcripts3
Announcements5
Intimation Of The Earnings Call Proposed To Be Held On November 04, 2026, At 02:30 PM IST 26 Oct - Q2 and half-year FY2026-27 earnings call on November 4, 2026 at 2:30 PM IST.Announcement under Regulation 30 (LODR)-Change in Management 26 Oct - Mr. Gagan Sharma appointed Senior Management Personnel effective October 26, 2026.Announcement under Regulation 30 (LODR)-Newspaper Publication 14 Oct - Intimation of the Newspaper Advertisement made by the Company in Financial Express and Navshakti today i.e. October 14, 2026, w.r.t. the completion of dispatch of …Notice Of Postal Ballot (02/2026-27) - Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 ('Listing Regulations') Of Evonile Pharma Limited (Formerly Known As Novartis India Limited ('The Company'). 13 OctCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 13 Oct - Regulation 74(5) certificate filed for quarter and half year ended September 30, 2026.